Form 4: BioLargo CSO Acquires Shares, Converts Debt to Equity

BioLargo's Chief Science Officer, Kenneth Reay Code, acquired 313,754 shares of common stock by converting salary and expense debt, subject to a lock-up agreement.

Summary

• Kenneth Reay Code, BioLargo's Director and Chief Science Officer, acquired 313,754 shares of common stock.
• The acquisition occurred on November 14, 2025, at a price of $0.16 per share.
• These shares were received in exchange for a reduction in amounts owed by BioLargo to Mr. Code for salary and unreimbursed business expenses.
• The newly acquired shares are subject to a lock-up agreement, restricting their sale until BioLargo reports gross revenue of at least $40 million, its market capitalization exceeds $300 million, or a change in control occurs.
• Following this transaction, Mr. Code beneficially owns a total of 25,751,505 shares, including 22,139,012 shares held indirectly through a wholly-owned corporation.

Sentiment

Score: 6

Explanation: The conversion of debt to equity is generally positive for the company's balance sheet, and insider buying, even for debt, can signal confidence. However, the lock-up agreement indicates future performance hurdles for liquidity.

Positives

• Insider acquisition of shares, which can signal confidence in the company's future prospects.
• Conversion of company debt (salary and expenses) into equity, reducing the company's liabilities.

Negatives

• The lock-up agreement restricts the immediate liquidity of the acquired shares for the reporting person.

Risks

• The acquired shares are subject to a lock-up agreement, meaning they cannot be sold until specific financial or corporate milestones are met (gross revenue of $40 million, market cap of $300 million, or change in control).

Future Outlook

The lock-up agreement conditions (achieving $40 million in gross revenue or $300 million market capitalization) implicitly set future performance targets for the company that would allow the reporting person to sell their acquired shares.

Management Comments

• The shares issued are subject to a Lock-Up Agreement dated as of the issuance date whereby shares are locked-up and restricted from sale until the Issuer reports gross revenue of at least $40 million on a consolidated basis for any reported period (e.g, quarter or annual), or the Issuer's market capitalization exceeds $300 million, or there is a 'change in control' in the Issuer.
• Shares received from Issuer in exchange for a reduction in amounts owed by Issuer to Reporting Person for salary and unreimbursed business expenses (equal to the product of the number of shares and acquisition price per share).

Industry Context

This Form 4 filing is a standard disclosure of insider trading and does not provide broader industry context or trends. It primarily focuses on an individual's transaction within the company.

Corporate Governance

Related Party Transactions

• Kenneth Reay Code, as a Director and Chief Science Officer, received 313,754 shares of common stock from BioLargo, Inc. in exchange for a reduction in salary and unreimbursed business expenses owed by the company to him.

Stakeholder Impact

• Shareholders: The issuance of new shares for debt conversion could lead to minor dilution, but it also reduces company liabilities. Insider ownership increase might be viewed positively.
• Kenneth Reay Code (Reporting Person): Converts outstanding debt into equity, aligning his interests further with the company's long-term success, but subject to a lock-up period.
• Company (BioLargo, Inc.): Reduces current liabilities by converting debt to equity, improving its balance sheet.

Next Steps

• BioLargo to work towards achieving gross revenue of at least $40 million or a market capitalization exceeding $300 million to release the lock-up on the acquired shares.

Key Dates

Recommendation

While the insider acquisition of shares, even through debt conversion, can be seen as a positive signal of confidence, a Form 4 filing alone does not provide sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. The lock-up agreement ties the liquidity of these shares to significant future performance milestones, suggesting a long-term view but also highlighting the current need for substantial growth. Investors should 'hold' and await more comprehensive financial reports to assess the company's progress towards these targets and overall financial health.

Keywords

BioLargo, BLGO, SEC Form 4, Insider Trading, Stock Acquisition, Chief Science Officer, Equity Conversion, Debt to Equity, Lock-Up Agreement, Beneficial Ownership